Press Release FeedGet the RSS feed
Menu

GlobeNewswire

INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

GlobeNewswire

BOCA RATON, Fla., Oct. 21, 2026 -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has updated its regulatory submission strategy, as faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.

  1. Coppernico Announces Upcoming Investor Conference Schedule Ahead of Phase 2 Drilling at SombreroCoppernico Metals Inc. (TSX: COPR, OTCQB: CPPMF, FSE: 9I3) (“Coppernico” or the “Company”) is pleased to announce its participation in several upcoming investor conferences across North America and Europe, where Chair and CEO Ivan Bebek will highlight the Company's corporate strategy and planned Phase 2 drill program at its flagship copper-gold Sombrero Project in Peru, as the Company advances preparations for its next phase of exploration.
  2. HealthcareKyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS TorontoMiv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies
  3. FinanceUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027.
  4. EnergyWISDOMTREE WTI CRUDE OIL 3X DAILY SHORT SECURITIES ISIN: XS2819844387 PROPOSED AMENDMENT TO THE PRINCIPAL AMOUNT OF THE AFFECTED SECURITIES MEETING OF THE ETP SECURITYHOLDERS21 October 2026
  5. IndustrialAustin Roofing Awarded Major Steel Roof Restoration at Parts Canada Corporate Headquarters in London, OntarioAustin Roofing & Waterproofing Incorporated, recognized as Canada’s largest commercial and industrial roofing coatings contractor, has secured another major industrial steel roof restoration project at the Parts Canada corporate headquarters in London, Ontario.
  6. Form 8.3 - Brave Bison Group PlcDowning LLP LEI: 213800G3X76VBG9SB504 21 October 2026 Form 8.3 re. Brave Bison Group Plc